Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lilly Poised To Cut R&D Spending In 2014

by Rick Mullin
January 13, 2014 | A version of this story appeared in Volume 92, Issue 2

[+]Enlarge
Credit: Eli Lilly & Co
A Lilly researcher in Shanghai.
A man in PPE works at a computer near HPLC-type instrumentation.
Credit: Eli Lilly & Co
A Lilly researcher in Shanghai.

Eli Lilly & Co. says its profits will decline by as much as one-third this year on estimated revenue between $19.2 billion and $19.8 billion. The company also says that R&D expenditures for the year will range between $4.4 billion and $4.7 billion, a cut of about $1 billion from last year. Lilly faces a hit on the loss of patent protection for its antidepressant Cymbalta and its osteoporosis drug Evista by the end of the first quarter of 2014. A holdout among the major drug companies on restructuring R&D, Lilly has experienced a number of late-stage clinical failures, recently of ramucirumab, a breast cancer therapy candidate.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.